Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We have found that the expression of p53 messenger RNA is growth regulated in human cells following kinetics similar to that previously shown in mouse 3T3 cells, and is increased in the large majority of colon adenocarcinomas in comparison to adjacent normal mucosa and adenoma.
|
3019534 |
1986 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry.
|
2137812 |
1990 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We analyzed 15 aneuploid populations and one tetraploid populations from 13 Barrett's adenocarcinomas for 17p allelic deletions and p53 protein overexpression to determine whether both of these alterations are involved in carcinogenesis in Barrett's esophagus.
|
1680552 |
1991 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Mucinous carcinomas and right-side carcinomas were less p53 immunoreactive (25% and 52%, respectively) than the usual adenocarcinomas (73%) and distal tumors (72%).
|
1868464 |
1991 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although the number of p53 negative adenocarcinomas without metastasis was larger than the number of p53 positive tumors without metastasis, there were not clear differences between p53 positive and negative tumors with metastasis.
|
1656762 |
1991 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
However, the finding of p53 mutations in Barrett's epithelium adjacent to adenocarcinomas may have clinical implications for p53 as a premalignant marker for esophageal cancer.
|
1943188 |
1991 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Our study indicates that there might be an association between accumulation of p53 protein and c-myc over-expression in non-small-cell lung cancer, and that this in particular might apply to adenocarcinomas.
|
1334053 |
1992 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53 protein in a high proportion of advanced stage serous adenocarcinomas.
|
1310251 |
1992 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Among four adenocarcinomas arising in the lowest portion of the uterine corpus, three showed integration of human papillomavirus (HPV) types 16 and/or 18 DNA, and two of them also showed p53 mutation.
|
1336492 |
1992 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining for the p53 protein was performed in 107 snap frozen primary endometrial adenocarcinomas and 15 benign uterine tissues using monoclonal antibody PAb1801.
|
1540970 |
1992 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
|
1552612 |
1992 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this study we investigated immunohistochemically the expression of p53 and c-erbB-2 proteins in 30 gall bladder adenocarcinomas, one carcinoma in situ, eight gall bladder epithelial dysplasias, and four cases of chronic cholecystitis. p53 expression could be found in 14 (47 per cent) adenocarcinomas and in two out of eight epithelial dysplasias.
|
8100854 |
1993 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Mutant P53 protein was present in 58.6 percent of anal cancers overall and in 85.7 percent of anal adenocarcinomas.
|
8223054 |
1993 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
To reveal the role of the p53 tumor suppressor gene in the development of endometrial adenocarcinoma and to study the association of p53 alterations with K-ras activation, an additional 28 endometrial adenocarcinomas and an additional 11 premalignant atypical uterine hyperplasias (series 3), as well as 12 cases of endometrial adenocarcinoma (10 having K- or N-ras activation) and 2 cases of atypical hyperplasia from series 1 and 2, were screened for the presence of p53 alterations.
|
8385572 |
1993 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry with PAb 1801 monoclonal antibody was performed on archival material; p53 nuclear staining was seen in 10/17 adenomas, but was limited to the foci of adenocarcinoma in three cases.
|
8237942 |
1993 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
DNA sequence and single strand conformational polymorphism analyses were used to evaluate p53 in 27 squamous carcinomas (25 HPV-positive) and eight adenocarcinomas (four HPV-positive).
|
8238255 |
1993 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Seven cases showed p53 gene mutations: four advanced-stage adenocarcinomas, the papillary carcinoma, the neuroendocrine carcinoma, and the adenoma with foci of carcinoma.
|
8475992 |
1993 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Pancreatic adenocarcinomas frequently show p53 gene mutations.
|
8494051 |
1993 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Eight of 11 adenocarcinomas overexpressed the p53 protein.
|
8496390 |
1993 |
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Conversely, the development of poorly differentiated adenocarcinoma, in addition to changes in p53 and c-met genes, requires reduction or dysfunction of cadherin.
|
8440743 |
1993 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Although p53 was expressed more commonly in adenocarcinoma (30% of 10) and squamous carcinoma (28% of 29) than in small cell tumors (10% of 20), this could be accounted for by the smoking history.
|
8390213 |
1993 |
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Pancreatic expression of the p53 tumor suppressor gene was studied in pancreatic adenocarcinomas and chronic pancreatitis.
|
8513440 |
1993 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Two adenocarcinomas with allelic loss on 17p contained a mutant p53 gene in the allele that was retained.
|
8473053 |
1993 |
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Progression to the adenocarcinoma phenotype was shown to involve a specific chromosome 1 rearrangement, loss of both normal copies of chromosome 18 (although DCC gene sequences were retained), loss of the remaining wild type allele of k-ras resulting in homozygosity for the k-ras codon 12 mutation and increased cellular p53 protein as detected by SDS-PAGE Western blotting.
|
8414507 |
1993 |